Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.

MAIA’s ongoing pivotal Phase 3 trial THIO-104 evaluates ateganosine sequenced with checkpoint inhibitor cemiplimab versus investigator’s choice in third-line non-small cell lung cancer (NSCLC). Statistical assessments of ateganosine suggest a high probability of technical success and potential early full commercial approval if Phase 3 interim data is consistent with Phase 2 THIO-101 trial results. MAIA recently announced positive initial efficacy data from the ongoing Phase 2 THIO-101 clinical trial expansion, Part C, with third-line studies showing a disease control rate (DCR) of 90.5%1 in the efficacy evaluable population who had at least one tumor scan after starting treatment.

As of September 14, 2026, MAIA’s directors and officers hold a 21.34% stake in the Company.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.